A phase I open-labeled, dose-escalation, safety study of the combination of Velcade [bortezomib] and chemoradiation for the treatment of cancer patients.
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs Antineoplastics; Bortezomib
- Indications Cervical cancer; CNS cancer; Head and neck cancer; Solid tumours
- Focus Adverse reactions
- 19 Aug 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 19 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jul 2007 New trial record.